Dec 16, 2025
The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration’s aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pharmaceutical industry veteran with experience in Big 4, brand drugs, biosimilars,...
Dec 15, 2025
Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner’s National Priority Voucher program, the “plausible mechanism” pathway for personalized therapies, and new draft guidance aimed at streamlining biosimilars and interchangeables. Join Washington, D.C. partner
Nov 24, 2025
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak, Managing Director at Ernst & Young LLP, joins...
Nov 3, 2025
The new FDA Commissioner’s National Priority Voucher (CNPV) pilot program promises to reduce recipients’ application review times from 10-12 months to just 1-2 months. As part of the Trump administration’s push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA’s...
Oct 2, 2025
Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott, counsel Nicole Liffrig...